Palbociclib 125mg: Clinical Trials

3 recruiting, 1 completed, 1 terminated. 5 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Recruiting 3, Completed 1, Terminated 1
Phase 2	2	Recruiting 1, Terminated 1

Follow Palbociclib 125mg: new trials by email Literature Review of Palbociclib 125mg trials Research Report on Palbociclib 125mg

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet - Metastatic Breast Cancer, Breast Cancer Stage I	Phase 1 / Phase 2	Recruiting	Forward Pharmaceuticals Co., Ltd.	196	2025-06-01	2026-01-07
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA SNP, Palbociclib 125mg, Bevacizumab - Cancer, Solid Tumor	Phase 1	Recruiting	Lebanese University	50	2023-02-15	2024-03-12
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer RLY-2608, Fulvestrant, Palbociclib 125mg - PIK3CA Mutation, Solid Tumor, Adult	Phase 1	Recruiting	Relay Therapeutics, Inc.	930	2021-12-08	2025-09-22
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Palbociclib 75mg, Letrozole 2.5mg, T-DM1 - HER2-positive Breast Cancer, Breast Cancer Metastatic	Phase 1 / Phase 2	Terminated	University of Kansas Medical Center	3	2018-10-15	2024-03-05
A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg - Healthy	Phase 1	Completed	Pfizer	27	2014-03-01	2014-06-24

Conditions studied

Breast Neoplasms (3)  ·  Colorectal Neoplasms (1)  ·  Inflammation (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)

Sponsors

Forward Pharmaceuticals Co., Ltd. (1)  ·  Lebanese University (1)  ·  Pfizer (1)  ·  Relay Therapeutics, Inc. (1)  ·  University of Kansas Medical Center (1)

Countries

United States (3)  ·  Australia (1)  ·  China (1)  ·  France (1)  ·  Italy (1)  ·  Lebanon (1)  ·  Spain (1)

Top investigators

Lauren Nye, MD (1)  ·  Nehman Makdissy, Professor (1)